Prognostication of Recovery in Patients With Acute Ischemic Stroke Through the Use of Brain SPECT With Technetium-99m—Labeled Metronidazole

  • Ho-Chun Song
    From the Departments of Nuclear Medicine (H-C.S., H-S.B.), Neurology (K.H.C., B.C.K.), and Diagnostic Radiology (J-J.S.), Chonnam National University Hospital, Gwangju, South Korea; Department of Nuclear Medicine (C-G.K.), Wonkwang University Hospital, Iksan, South Korea; and Department of Nuclear Medicine (D.J.Y., E.E.K.), University of Texas MD Anderson Cancer Center, Houston, Tex.
  • Hee-Seung Bom
    From the Departments of Nuclear Medicine (H-C.S., H-S.B.), Neurology (K.H.C., B.C.K.), and Diagnostic Radiology (J-J.S.), Chonnam National University Hospital, Gwangju, South Korea; Department of Nuclear Medicine (C-G.K.), Wonkwang University Hospital, Iksan, South Korea; and Department of Nuclear Medicine (D.J.Y., E.E.K.), University of Texas MD Anderson Cancer Center, Houston, Tex.
  • Ki Hyun Cho
    From the Departments of Nuclear Medicine (H-C.S., H-S.B.), Neurology (K.H.C., B.C.K.), and Diagnostic Radiology (J-J.S.), Chonnam National University Hospital, Gwangju, South Korea; Department of Nuclear Medicine (C-G.K.), Wonkwang University Hospital, Iksan, South Korea; and Department of Nuclear Medicine (D.J.Y., E.E.K.), University of Texas MD Anderson Cancer Center, Houston, Tex.
  • Byeong Chae Kim
    From the Departments of Nuclear Medicine (H-C.S., H-S.B.), Neurology (K.H.C., B.C.K.), and Diagnostic Radiology (J-J.S.), Chonnam National University Hospital, Gwangju, South Korea; Department of Nuclear Medicine (C-G.K.), Wonkwang University Hospital, Iksan, South Korea; and Department of Nuclear Medicine (D.J.Y., E.E.K.), University of Texas MD Anderson Cancer Center, Houston, Tex.
  • Jeong-Jin Seo
    From the Departments of Nuclear Medicine (H-C.S., H-S.B.), Neurology (K.H.C., B.C.K.), and Diagnostic Radiology (J-J.S.), Chonnam National University Hospital, Gwangju, South Korea; Department of Nuclear Medicine (C-G.K.), Wonkwang University Hospital, Iksan, South Korea; and Department of Nuclear Medicine (D.J.Y., E.E.K.), University of Texas MD Anderson Cancer Center, Houston, Tex.
  • Chang-Guhn Kim
    From the Departments of Nuclear Medicine (H-C.S., H-S.B.), Neurology (K.H.C., B.C.K.), and Diagnostic Radiology (J-J.S.), Chonnam National University Hospital, Gwangju, South Korea; Department of Nuclear Medicine (C-G.K.), Wonkwang University Hospital, Iksan, South Korea; and Department of Nuclear Medicine (D.J.Y., E.E.K.), University of Texas MD Anderson Cancer Center, Houston, Tex.
  • David J. Yang
    From the Departments of Nuclear Medicine (H-C.S., H-S.B.), Neurology (K.H.C., B.C.K.), and Diagnostic Radiology (J-J.S.), Chonnam National University Hospital, Gwangju, South Korea; Department of Nuclear Medicine (C-G.K.), Wonkwang University Hospital, Iksan, South Korea; and Department of Nuclear Medicine (D.J.Y., E.E.K.), University of Texas MD Anderson Cancer Center, Houston, Tex.
  • E. Edmund Kim
    From the Departments of Nuclear Medicine (H-C.S., H-S.B.), Neurology (K.H.C., B.C.K.), and Diagnostic Radiology (J-J.S.), Chonnam National University Hospital, Gwangju, South Korea; Department of Nuclear Medicine (C-G.K.), Wonkwang University Hospital, Iksan, South Korea; and Department of Nuclear Medicine (D.J.Y., E.E.K.), University of Texas MD Anderson Cancer Center, Houston, Tex.

抄録

<jats:p> <jats:bold> <jats:italic>Background and Purpose—</jats:italic> </jats:bold> We hypothesized that technetium-99m-ethylene dicysteine-metronidazole ( <jats:sup>99m</jats:sup> Tc-EC-MN) localizes to brain tissue that is hypoxic but viable. This study prospectively evaluated the relationship between neurological outcome and uptake of <jats:sup>99m</jats:sup> Tc-EC-MN in peri-infarcted regions of the brain. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods—</jats:italic> </jats:bold> Eight patients with acute ischemic stroke in the territory of the left middle cerebral artery underwent <jats:sup>99m</jats:sup> Tc-EC-MN and <jats:sup>99m</jats:sup> Tc-ethyl cysteinate dimer (ECD) brain SPECTs on the same day during the subacute stage (10.3±2.5 days). The infarct volumes from <jats:sup>99m</jats:sup> Tc-ECD images (IV <jats:sub>ECD</jats:sub> ), infarct volumes from diffusion-weighted MRI images (IV <jats:sub>DW</jats:sub> ), and hypoxic volume (HV) from <jats:sup>99m</jats:sup> Tc-EC-MN images were calculated. The net infarct volume (NIV <jats:sub>ECD</jats:sub> ) was defined as IV <jats:sub>ECD</jats:sub> minus HV. The National Institutes of Health Stroke Scale scores were measured on admission and days 1, 3, 7, and 30. </jats:p> <jats:p> <jats:bold> <jats:italic>Results—</jats:italic> </jats:bold> IV <jats:sub>ECD</jats:sub> was greater than IV <jats:sub>DW</jats:sub> . The lesion-to-normal count-density ratios of <jats:sup>99m</jats:sup> Tc-EC-MN ranged from 1.80 to 5.96. HV was 60.2±65.2 cm <jats:sup>3</jats:sup> , and the mean percent HV was 24.5±28.1% of IV <jats:sub>ECD</jats:sub> . NIV <jats:sub>ECD</jats:sub> was 162.6±133.4 cm <jats:sup>3</jats:sup> and was significantly smaller than IV <jats:sub>ECD</jats:sub> . NIV <jats:sub>ECD</jats:sub> was significantly correlated with National Institutes of Health Stroke Scale score at 1 month and was a significant predictor of neurological deficit at 1 month. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> <jats:sup>99m</jats:sup> Tc-EC-MN brain SPECT can detect hypoxic tissue after acute ischemic stroke and, in combination with <jats:sup>99m</jats:sup> Tc-ECD brain SPECT, is useful in predicting neurological outcome in ischemic stroke patients. </jats:p>

収録刊行物

  • Stroke

    Stroke 34 (4), 982-986, 2003-04

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ